Gene expression profile analysis of WT and LGP2-/- bone-marrow derived dendritic cells treated with a RIG-I agonist

We performed RNAseq analysis on WT and LGP2-/- BM-DCs treated with a RIG-I agonist (HCV Poly-U/C RNA) to understand how LGP2 impacts global transcriptional changes following activation of the RIG-I pathway. Analysis of the transcriptional profiles revealed that LGP2 functions as a negative regulator of RIG-I signaling as early as 1 hours post-RIG-I agonist treatment. This finding led us to study how LGP2 negatively influences RIG-I activation through post-translational modification. Overall design: Bone-marrow derived dendritic cells were generated from WT (C57BL/6J) and LGP2-/- mice. BM-DCs were treated with a RIG-I agonist (HCV Poly-U/C RNA). At 1, 3 and 6 hours post-treatment, time-matched mock and RIG-I agonist cells were collected for RNAseq analysis.